Dr. Willi's research focuses on therapeutics for type 1 and type 2 diabetes and he has performed a number of physiologic studies in the etiology and characterization of diabetes in children. His current studies include trials on the delay of progression of type 1 diabetes and a multicenter trial to examine the optimal therapeutics for type 2 diabetes in children.
Earlier this year, the American Academy of Pediatrics recognized Dr. Schmidt with the William A. Silverman Lectureship Award. The award recognizes an individual whose work has significantly advanced neonatal ethics or the field of neonatal evidence-based medicine.
Onwards and upwards: Last week's grand opening of the new Roberts Center for Pediatric Research coincided with a series of exciting news that suggest breakthroughs are on the horizon, and also give us a sense of how far research at Children's Hospital of Philadelphia has come.
Caffeine therapy can help premature babies breathe stronger and sooner on their own. When a group of caffeine-treated premature babies reached middle school, the therapy appeared to reduce their risk of motor impairment ‚Äì building on earlier follow-ups that show the treatment's safety, efficacy, and developmental benefits for the babies at one-and-a-half years old.
Sometimes half is better than whole. That's the idea behind a new multicenter study that Children's Hospital of Philadelphia is participating in to compare a five-day (short) course of antibiotic therapy with a 10-day (standard) course of therapy to treat community-acquired pneumonia (CAP) in children. Pneumonia is a lung infection that is the leading infectious cause of death in children